1. Home
  2. ANVS vs MAIA Comparison

ANVS vs MAIA Comparison

Compare ANVS & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ANVS
  • MAIA
  • Stock Information
  • Founded
  • ANVS 2008
  • MAIA 2018
  • Country
  • ANVS United States
  • MAIA United States
  • Employees
  • ANVS N/A
  • MAIA N/A
  • Industry
  • ANVS Biotechnology: Pharmaceutical Preparations
  • MAIA Biotechnology: Pharmaceutical Preparations
  • Sector
  • ANVS Health Care
  • MAIA Health Care
  • Exchange
  • ANVS Nasdaq
  • MAIA Nasdaq
  • Market Cap
  • ANVS 110.4M
  • MAIA 62.4M
  • IPO Year
  • ANVS 2020
  • MAIA 2022
  • Fundamental
  • Price
  • ANVS $9.57
  • MAIA $2.82
  • Analyst Decision
  • ANVS Strong Buy
  • MAIA
  • Analyst Count
  • ANVS 6
  • MAIA 0
  • Target Price
  • ANVS $29.67
  • MAIA N/A
  • AVG Volume (30 Days)
  • ANVS 341.4K
  • MAIA 60.0K
  • Earning Date
  • ANVS 11-06-2024
  • MAIA 11-05-2024
  • Dividend Yield
  • ANVS N/A
  • MAIA N/A
  • EPS Growth
  • ANVS N/A
  • MAIA N/A
  • EPS
  • ANVS N/A
  • MAIA N/A
  • Revenue
  • ANVS N/A
  • MAIA N/A
  • Revenue This Year
  • ANVS N/A
  • MAIA N/A
  • Revenue Next Year
  • ANVS N/A
  • MAIA N/A
  • P/E Ratio
  • ANVS N/A
  • MAIA N/A
  • Revenue Growth
  • ANVS N/A
  • MAIA N/A
  • 52 Week Low
  • ANVS $4.53
  • MAIA $0.82
  • 52 Week High
  • ANVS $22.49
  • MAIA $5.99
  • Technical
  • Relative Strength Index (RSI)
  • ANVS 58.70
  • MAIA 50.98
  • Support Level
  • ANVS $9.00
  • MAIA $2.36
  • Resistance Level
  • ANVS $10.54
  • MAIA $2.72
  • Average True Range (ATR)
  • ANVS 0.81
  • MAIA 0.22
  • MACD
  • ANVS 0.12
  • MAIA 0.02
  • Stochastic Oscillator
  • ANVS 74.57
  • MAIA 72.28

About ANVS Annovis Bio Inc.

Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for advanced AD.

About MAIA MAIA Biotechnology Inc.

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company. The company develops targeted immunotherapies for cancer. The company is an immune-oncology company, focused on the development of first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. The company's program is THIO, a potential cancer telomere-targeting agent in clinical development for the treatment of telomerase-positive cancer cells.

Share on Social Networks: